Compare PCRX & FWRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | FWRD |
|---|---|---|
| Founded | 2006 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil Refining/Marketing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 871.2M |
| IPO Year | 2010 | 2024 |
| Metric | PCRX | FWRD |
|---|---|---|
| Price | $22.00 | $21.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $35.33 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 739.7K | 602.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | $541,533,000.00 | ★ $1,269,573,000.00 |
| Revenue This Year | $9.77 | $6.77 |
| Revenue Next Year | $9.71 | $6.83 |
| P/E Ratio | $142.97 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $9.79 |
| 52 Week High | $27.99 | $32.47 |
| Indicator | PCRX | FWRD |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 29.02 |
| Support Level | $20.41 | $16.46 |
| Resistance Level | $23.82 | $23.20 |
| Average True Range (ATR) | 1.00 | 1.44 |
| MACD | -0.00 | -0.50 |
| Stochastic Oscillator | 43.41 | 7.39 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in the United States, Canada, and Mexico.